Clinical Trial Update: Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating axitinib as first-line treatment for advanced or metastatic papillary renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Papillary Renal Cell Carcinoma

Drugs mentioned

• Axitinib (Axitinib)

Snippet

Sponsor: Centre Leon Berard | Conditions: Papillary Renal Cell Carcinoma | Phase 2 | Status: COMPLETED